New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
11:18 EDTHLF, RPRX, CSTR, ACAD, EXCOptions with increasing implied volatility: HLF RPRX CSTR ACAD EXC
News For HLF;RPRX;CSTR;ACAD;EXC From The Last 14 Days
Check below for free stories on HLF;RPRX;CSTR;ACAD;EXC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:01 EDTEXCComEd awarded grant from Energy Department for microgrid controller
Subscribe for More Information
September 15, 2014
12:14 EDTHLFHerbalife expands partnership with American Youth Soccer Organization
Subscribe for More Information
09:32 EDTACADACADIA management to meet with JPMorgan
Subscribe for More Information
September 14, 2014
16:17 EDTHLFHerbalife near settlement with former distributors, NY Post says
Herbalife is close to reaching a settlement with five former distributors that allege the nutrition company is a pyramid scheme and has victimized thousands, says the NY Post. Reference Link
September 12, 2014
10:10 EDTACADHigh option volume stocks
Subscribe for More Information
September 5, 2014
09:10 EDTHLFHerbalife distributor claims fired for web sales, Seeking Alpha contributor says
Subscribe for More Information
September 4, 2014
07:36 EDTRPRXRepros Therapeutics weakness a buying opportunity, says Brean Capital
Brean Capital said the recent weakness in Repros Therapeutics is a buying opportunity. The firm said concerns over the upcoming FDA meeting are overblown and shares were substantially oversold in response to negative commentary yesterday. Shares of Repros Therapeutics remain Buy rated with a $41 price target.
September 3, 2014
16:20 EDTRPRXOn The Fly: Closing Wrap
Stocks on Wall Street began the session in positive territory after Russian President Vladimir Putin said he had an outline for a cease-fire plan for eastern Ukraine and was closing in an agreement. The averages hit their highs shortly after the open and the Nasdaq was the first index to cross into negative territory as it was weighed down by Apple's (AAPL) decline. The market moved in a narrow range as investors anticipated the Fedís Beige Book report, scheduled for release mid-afternoon. The report was fairly benign and the market limped into the close, with volume remaining light. ECONOMIC EVENTS: U.S. factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book stated that the pace of growth did not change significantly in any of the central bank's 12 regions during a six week period ended in August compared with the previous six week period. COMPANY NEWS: Shares of Apple retreated $4.36, or 4.22%, to $98.94 after research firm Pacific Crest advised investors to take some profits in the stock. Analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which surged $4.81, or 44.05%, to $15.73 after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which jumped $3.94, or 9.16%, to $46.97 ahead of its second quarter earnings report, which is due tomorrow morning. Among the noteworthy losers was Repros Therapeutics (RPRX), which fell $4.11, or 18.55%, to $18.05 after FDA briefing documents ahead of a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower after its earnings report was apparel company Vince Holding (VNCE), which fell $4.47, or 11.54%, to $34.27. Analysts at Piper Jaffray attributed the post-earnings weakness to investor concerns over heightened inventory levels, but the firm said it still sees Vince as one of the best small cap growth names in its space and would be "aggressive buyers" on the weakness. INDEXES: The Dow edged up 10.72, or 0.06%, to 17,078.28, the Nasdaq fell 25.62, or 0.56%, to 4,572.56, and the S&P 500 slipped 1.56, or 0.08%, to 2,000.72.
12:33 EDTRPRXOn The Fly: Midday Wrap
Stocks on Wall Street were higher to begin the day, as reports spurred optimism that a ceasefire agreement between Russia and the Ukraine may soon be reached. The move was short lived, as the averages turned mixed during the second hour of trading. Shares of Apple (AAPL) are weighing down the Nasdaq after an analyst recommended investors take some profits in the stock. ECONOMIC EVENTS: In the U.S., factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book is scheduled to be released at 2:00 pm ET. In Europe, the final reading of Eurozone services PMI was knocked down to 53.1 from a preliminary 53.5 reading, mirroring the lowering of the Eurozone manufacturing PMI reading yesterday. COMPANY NEWS: Shares of Apple retreated 4% after research firm Pacific Crest advised investors to take some profits in the stock. Pacific Crest analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event... Carmakers reported on August vehicle sales in the U.S., with Chrysler (FIATY) reporting a 20% increase, Ford stating that sales rose slightly compared to the prior year and General Motors (GM) posting a 1.2% decline in sales. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which jumped 46% after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which gained nearly 10% after Morgan Stanley wrote that the stock could rise "towards $100" if the company maintains its current market, gross margins and earnings position. Mobileye is scheduled to report on its second quarter results tomorrow morning, which will be its first quarterly report since its August IPO. Among the noteworthy losers was Repros Therapeutics (RPRX), which dropped 15% after newly posted FDA briefing documents regarding a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower following its earnings report was apparel company Vince Holding (VNCE), which fell 11%. INDEXES: Near midday, the Dow was up 33.71, or 0.2%, to 17,101.27, the Nasdaq was down 23.24, or 0.51%, to 4,574.95, and the S&P 500 was down 0.64, or 0.03%, to 2,001.64.
11:34 EDTACADACADIA price target raised to $28.50 at Ladenburg after breakthrough status
Subscribe for More Information
11:13 EDTRPRXRepros Therapeutics downgraded to Neutral at Piper Jaffray
Subscribe for More Information
11:09 EDTRPRXRepros Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:23 EDTEXCUranerz Energy makes first Uranium delivery
Uranerz Energy (URZ) announced that it has delivered its first drums of uranium, as U3O8, produced from its wholly-owned Nichols Ranch ISR Uranium Project in the Powder River Basin of Wyoming, U.S.A. The shipment of approximately 36,000 pounds was received at ConverDyn's Metropolis Works Facility, located in Metropolis, Illinois, for subsequent transfer to one of the company's utility customers. Uranerz signed its first long-term uranium sales agreement in 2009 with Exelon Generation Company (EXC), and signed its second sales agreement with another major U.S. utility later that same year. This delivery will satisfy a portion of Uranerz' existing long-term sales contracts and the company expects to make its next shipment of uranium later this quarter.
September 2, 2014
11:43 EDTHLFChina announces 'major' busts as result of pyramid probe, Shanghai Daily reports
Subscribe for More Information
09:03 EDTACADACADIA receives FDA breakthrough therapy designation for Nuplazid
ACADIA Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to NUPLAZID for the treatment of Parkinsonís disease psychosis. NUPLAZID is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinsonís disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application. ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use